CAROLE JOLLEY: Open Payments
NPI 1932982006 · SHELBY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,346 in 389 payments from 22 companies in 2025. Trend: 2023 $1,165 · 2024 $5,034 · 2025 $6,346
Food & beverage: $6,245Education: $101
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 71 | $1,349 |
| ABBVIE INC. | 104 | $935 |
| Teva Pharmaceuticals USA, Inc. | 23 | $584 |
| Alkermes, Inc. | 22 | $423 |
| Otsuka America Pharmaceutical, Inc. | 27 | $326 |
| E.R. Squibb & Sons, L.L.C. | 15 | $320 |
| Janssen Pharmaceuticals, Inc | 18 | $307 |
| Axsome Therapeutics, Inc. | 13 | $296 |
| Vanda Pharmaceuticals Inc. | 14 | $293 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $262 |
Products named: INGREZZA, VRAYLAR, REXULTI, AUSTEDO XR, ARISTADA, COBENFY, Auvelity, FANAPT.
Industry payments across NC — which companies pay providers there.
